Viral myocarditis
diseaseOn this page
Summary
Viral myocarditis (MONDO:0023161) is a disease and 7 clinical trials. A subtype of myocarditis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | viral myocarditis |
| Mondo ID | MONDO:0023161 |
| ICD-10-CM | B33.22 |
| ICD-11 | 231270764 |
| NCIT | C128381 |
| SNOMED CT | 89141000 |
| UMLS | C0276138 |
| MedGen | 547112 |
| GARD | 0025370 |
| Is cancer (heuristic) | no |
Also known as: viral myocarditis
Disease family
This is a subtype of myocarditis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › cardiomyopathy › intrinsic cardiomyopathy › myocarditis › viral myocarditis
Related subtypes (6): Fiedler’s myocarditis, bacterial myocarditis, acute myocarditis, interstitial myocarditis, rheumatic myocarditis, autoimmune myocarditis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 7 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06742008 | Not specified | RECRUITING | Assessment of the Predictive Value of Anti-beta1AR and Anti-L-CaC Antibodies in the Evolution to Dilated Cardiomyopathy in Patients With Acute Viral Myocarditis |
| NCT03219996 | Not specified | COMPLETED | Risk Factors for Predictors of In-hospital Death in Acute Fulminant Myocarditis |
| NCT03777839 | Not specified | COMPLETED | PET-FDG in Myocarditis |
| NCT04312490 | Not specified | COMPLETED | Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis |
| NCT04527835 | Not specified | UNKNOWN | Presentation, Clinical Course and Patterns of Myocardial Damage Due to Viral Myocarditis |
| NCT04726150 | Not specified | COMPLETED | Effect of CoVid-19 (CoronaVirusDisease-19) and Exercise on Myocardial Fibrosis and Ventricular Arrhythmias |
| NCT05398952 | Not specified | UNKNOWN | Post-COVID-19 Outpatient Care and Biomarkers |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.